Search

Maffucci syndrome is a rare condition that affects the skin and bones, particularly the limbs. It is characterized by multiple enchondromas (benign bone tumors) and lymphovascular proliferations, such as hemangiomas and venous malformations. Lymphatic malformations, specifically lymphangiomas, have been reported in a few cases. The syndrome is associated with genetic mutations and carries a risk of developing various malignancies. The article presents a case of Maffucci lymphangioma syndrome in a woman with lesions on her lower limb. A skin biopsy confirmed the diagnosis, and genetic testing revealed a mutation associated with Maffucci syndrome. The authors emphasize the importance of recognizing this condition and conducting appropriate follow-up due to the risk of malignant transformation and other malignancies. [Extracted from the article]

Introduction Methods Results Conclusions Severe recurrent aphthous stomatitis (RAS) represents a therapeutic challenge because of its impact on the patient's quality of life. Additionally, no approved systemic therapies are available. Roflumilast, a phosphodiesterase‐4 inhibitor, has shown promise in other inflammatory dermatological conditions. This study aimed to assess the characteristics, effectiveness, and safety of roflumilast in treating RAS in routine clinical practice.This is a single cohort ambispective observational study conducted in five Spanish centers. Twenty‐two patients with RAS treated with roflumilast participated. Data collection included demographic, clinical, and outcome variables. Statistical analysis compared the outcomes of 12 weeks of roflumilast treatment with a similar prior period without treatment.During treatment with roflumilast, a significant reduction in flare‐ups (88%) and oral ulcers (94%) was observed compared to the untreated period. A reduction in pain (66%) and ulcer duration (63%) was observed. Adverse effects (AEs) occurred in 13 patients, predominantly headache and gastrointestinal disturbances. Most of these were self‐limiting or manageable with dose adjustment. Treatment was withdrawn in three cases, mainly because of AEs.This study suggests that roflumilast may effectively treat RAS by reducing the number of flare‐ups and ulcers, their duration, and the symptomatology produced by the ulcers. In addition, roflumilast has a good safety profile, is well tolerated at low doses, and does not require close monitoring. These characteristics and its favorable economic profile make roflumilast a promising therapeutic option in this pathology. [ABSTRACT FROM AUTHOR]